TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07831577: A Randomized, Double-blind, Placebo-controlled, Phase 2/3, Study to Evaluate the Efficacy and Safety of an Intraarticular Injection of GNSC-001 in Participants With Osteoarthritis of the Knee

Sponsor: Genascence Corporation · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,468,800

Rescue Site Savings

+$8,880,990

Unlock Full NCT07831577 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07831577 Rescue Dossier →